Related Experiment Video
Updated: Oct 20, 2025

08:27
A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine
Published on: December 6, 2024
437
Viscoelastic Hemostatic Assays for Postpartum Hemorrhage
Alyson E Liew-Spilger1, Nikki R Sorg2, Toby J Brenner3
1Department of Obstetrics and Gynecology, University of Oklahoma College of Medicine, Oklahoma City, OK 73104, USA.
Journal of Clinical Medicine
|September 10, 2021
Summary
Viscoelastic hemostatic assays (VHAs) rapidly assess blood clot formation, aiding treatment for postpartum hemorrhage (PPH). Despite benefits, underuse stems from interpretation challenges and limited trials, highlighting a need for wider adoption.
Area of Science:
- Obstetrics and Gynecology
- Hematology
- Critical Care Medicine
Background:
- Postpartum hemorrhage (PPH) poses significant risks, necessitating effective methods for assessing hemostatic competence.
- Traditional methods for evaluating coagulation have limitations in providing real-time, comprehensive data.
- Viscoelastic hemostatic assays (VHAs) offer a dynamic assessment of clot formation and function.
Purpose of the Study:
- To highlight the importance and effectiveness of VHAs in managing PPH.
- To discuss the advantages of VHAs over conventional coagulation tests.
- To identify barriers to VHA adoption and propose solutions.
Main Methods:
- Review of current literature on VHAs in the context of PPH.
- Comparison of VHAs (thromboelastography, rotational thromboelastometry) with clinical observation and standard coagulation tests.
- Discussion of VHA applications in various obstetric and gynecologic conditions.
Main Results:
- VHAs provide a comprehensive, point-of-care assessment of hemostasis, evaluating the entire clotting process.
- Advantages include rapid results, serial monitoring capability, and assessment of all blood components' contributions.
- VHAs are applicable beyond PPH to conditions like uterine atony, preeclampsia, and coagulopathies.
Conclusions:
- VHAs are crucial for guiding blood component therapy and hemostatic management in PPH.
- Underutilization is linked to interpretation difficulties, lack of standardization, and insufficient large-scale clinical trials.
- There is a critical need for increased VHA utilization and research to improve obstetric patient outcomes.
Related Concept Videos
Introduction to Hemostasis
9.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
9.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K

